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Abstract: Ocular herpes simplex virus (HSV) infection remains a major cause of corneal 
blindness. Several topical and oral antiviral medications have been used to treat herpetic kera-
titis. Advances in topical ophthalmic antivirals have been made over the past several decades. 
The ﬁ  rst antivirals that were discovered were cytotoxic, while the antivirals developed more 
recently, such as acyclovir and ganciclovir, have exceeded these drugs in both efﬁ  cacy and 
tolerability. Commercially available outside of the US since 1996, ganciclovir ophthalmic gel, 
0.15% (GCV 0.15%, European tradename: Virgan®) is sold in more than 30 countries and has 
become the standard of care in treating acute herpetic keratitis. GCV 0.15% has been studied 
in animal models of ocular herpes, in healthy volunteers, and in several clinical studies. It has 
been found to be safe and effective at treating acute superﬁ  cial herpetic keratitis. Previous pre-
clinical studies of ganciclovir have shown activity against several common adenovirus strains 
and one recent clinical study demonstrated clinical effect against adenoviral conjunctivitis. 
This review is intended to provide a comprehensive overview of the GCV 0.15%, including a 
brief summary of the etiology and available treatments for ocular HSV, an explanation of GCV 
0.15% mechanism of action, a compendium of preclinical and clinical GCV 0.15% studies, and 
an introduction into new areas of interest involving this drug.
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Introduction
Herpes simplex keratitis remains one of the leading causes of corneal blindness in the 
US (Biser 2007) and in the industrialized world. Herpes simplex virus (HSV) infec-
tions are very common, with nearly 60% of the US population showing evidence of 
infection by age 5 (Biser 2006). Approximately 1% of infected patients develop ocular 
outbreaks, and 20,000 new primary cases of ocular herpes are diagnosed in the US 
each year (Liesegang 1991; Pavan-Langston 1994). The Rochester study, which was 
conducted between 1950 and 1982, found the incidence to be 8.4 primary cases per 
100,000/year in the US (Liesegang 1989; Liesegang et al 1989). One study conducted 
in Denmark found the incidence to be 12 cases per 100,000/year, while another study 
conducted in Denmark found the incidence to be 5.9 cases per 100,000/year (Norn 
1970; Mortensen and Sjolie 1979). Possible reasons for these variations in reported 
incidence include completeness of recording, variations in diagnostic criteria, lack of 
data sharing among health care providers, and the inability to delineate the appropri-
ate population base. A more recent epidemiologic study conducted in France from 
September 2002 to December 2002 found the incidence to be much higher. In this 
multicenter prospective study, Labetoulle et al (2005) concluded the overall incidence 
of herpetic keratitis to be 31.5 cases per 100,000/year. The incidence for new cases 
of herpetic keratitis was 13.2 per 100,000/year and for recurrent cases it was 18.3 per 
100,000/year. A summary of the incidence of ocular HSV is included in Table 1.Clinical Ophthalmology 2007:1(4) 442
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In the Herpes viridae family, 8 viruses are pathogenic for 
humans: herpes simplex virus type 1 (HSV1), herpes simplex 
virus type 2 (HSV2), varicella-zoster virus (VZV), cytomega-
lovirus (CMV), human herpesvirus type 6 (HHV6), human 
herpesvirus type 7 (HHV7), Epstein-Barr virus (EBV), and 
human herpesvirus type 8 (HHV8) (Ramel 1997). Of these 
8 viruses, HSV1 is responsible for most ocular lesions. 
In fact, 98% of non-neonate ocular infections are due to 
HSV1 (Robinet-Combes and Colin 1993). In contrast, neo-
natal ocular infections are caused predominantly by HSV2, 
which is associated primarily with genital herpes that can be 
transmitted to the neonate during passage through the birth 
canal; these ocular infections are typically more severe than 
HSV1 infections.
HSV ocular infections are characterized by a primary 
outbreak and subsequent recurrences. The primary outbreak 
typically occurs during childhood, but is usually mild or 
subclinical. If symptomatic infections occur, it typically 
presents as acute follicular conjunctivitis associated with 
palpebral ulceration, vesicles, or corneal microdendrites and 
preauricular adenopathies.
After the primary infection, HSV typically becomes 
quiescent or latent in the trigeminal ganglion or the cornea 
and conditions such as stress, UV radiation, and hormonal 
changes can reactivate the virus. Lesions are also common 
in immunosuppressed individuals such as recent organ trans-
plant patients or patients with HIV. These recurrent herpetic 
infections have a tendency to occur in the cornea and uvea 
and may cause dendritic (Figure 1) or geographic (Figure 2) 
corneal ulcers.
Initial recurrences of HSV keratitis typically present as 
epithelial disease, but subsequent recurrences may progress 
towards deeper layers resulting in stromal keratitis and/or 
anterior uveitis. Repeated outbreaks of herpes simplex viral 
infections involving the corneal stroma can ultimately lead 
to an alteration of the corneal transparency (Robinet-Combes 
and Colin 1993) (Figure 3).
The risk of blindness increases with the number and 
severity of recurrences, so prompt treatment of herpetic 
epithelial ulcers is imperative to limit scarring and other more 
serious complications that can lead to blindness.
Antiviral agents used to treat ocular 
herpes
While treatment of ocular HSV infection has advanced con-
siderably during the past 15 years, problems related to the 
epithelial toxicity of some available antiviral agents remain, 
and this toxicity is responsible for the continued epithelial 
lesions and the poor tolerance of these treatments (Maudgal 
et al 1983; Naito et al 1987).
Herpetic keratitis treatment is dependent on the manifesta-
tion and severity of the disease. Epithelial dendritic keratitis 
is most often treated with oral and/or topical antiviral therapy 
and corneal debridement, although the latter is becoming a 
less commonly used method. Five topically applied oph-
thalmic antivirals have been used in Europe and the United 
States. Four of these drugs include antiviral agents that target 
infected and healthy cells: idoxuridine (IDU), iododesoxy-
cytidine (IDC), vidarabine (Ara-A), and triﬂ  uridine (TFT). 
More recently developed topical antivirals, such as acyclovir 
(ACV) and ganciclovir, are more selective and less toxic than 
their predecessors.
IDU, IDC, and Ara-A were found to be very toxic and 
have since been abandoned by clinicians in favor of less 
harmful agents.
Table 1 Ocular herpes simplex virus incidence
Site Study  period  Incidence  Source
Rochester  1950–1982  8.4 primary cases per 100,000/year  Liesegang 1989; Liesegang et al 1989
Denmark  1970  12 primary cases per 100,000/year  Norn 1970
Denmark  1979  5.9 primary cases per 100,000/year  Mortensen and Sjolie 1979
France  September 2002   Overall incidence: 31.5 cases per 100,000/year  Labetoulle et al 2005
  to December 2002  Primary cases: 13.2 per 100,000/year
    Recurrent cases: 18.3 per 100,000/year
Figure 1 Dendritic corneal ulcer caused by herpes simplex virus keratitis.
All photographs have been obtained, and used with permission, from Yves Lackkar, 
Hôpital Saint-Joseph, 185 rue Raymond Losserand, 75014 Paris, France.Clinical Ophthalmology 2007:1(4) 443
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In the US, TFT (US tradename: Viroptic®) is the only 
antiviral agent currently available for topical ocular herpes 
treatment. TFT is a thymidine analogue which is activated 
by cell and viral thymidine kinase and is incorporated into 
the DNA of both the virus and host cells. It is effective for 
superﬁ  cial herpetic keratitis, but because it is non-selective 
and affects healthy cells as well as infected cells, it results 
in epithelial toxicity that can lead to permanent damage of 
the cornea, as well as blepharitis, cannicular occlusion, and 
allergies. TFT is usually prescribed one drop every 2 hours 
during waking hours up to a maximum of nine times per day 
in the infected eye, and should not be administered for more 
than 21 days because of potential ocular toxicity. Addition-
ally, ocular penetration is poor when the corneal epithelium 
is intact (Sugar et al 1980; Van Bijsterveld and Post 1980; 
La Lau et al 1982; Hovding 1989; Power et al 1991; Renard 
and Denis 1991; Robinet-Combes and Colin 1993). TFT is 
currently in use only in the US and Canada.
Outside the US, acyclovir ophthalmic ointment 3% 
(ACV 3%) and ganciclovir ophthalmic gel, 0.15% (GCV 
15%) are used as ﬁ  rst-line therapies for the treatment of acute 
superﬁ  cial herpetic keratitis.
Acyclovir and ganciclovir inhibit HSV infection and 
replication by similar pharmacologic mechanisms. Cellular 
and viral thymidine kinases convert ganciclovir and acyclovir 
into a triphosphate active derivative. This phosphorylation, 
or activation, is carried out primarily in infected cells. Once 
they are phosphorylated, acyclovir and ganciclovir inhibit the 
synthesis of viral DNA in two ways: competitive inhibition 
of viral DNA-polymerase and direct incorporation into the 
viral primer strand DNA, which results in viral DNA chain 
termination and prevention of viral replication (Hayden 
2001). Intracellular ganciclovir triphosphate concentrations 
are 10-fold higher than those of acyclovir triphosphate and 
decline much more slowly with an intracellular half life 
exceeding 24 hours (Biron 1985).
The structure and in vitro activity 
of ganciclovir
Ganciclovir is a synthetic nucleoside analogue of 2′-
deoxyguanosine. Its structure is 9-(1,3-dihydroxy-2-
propoxymethyl) guanine, and its molecular weight is 255.23 
(Figure 4).
Viral plaque reduction assays were used to test ganciclovir’s 
antiviral activity in vitro, and ganciclovir was found to be a 
powerful inhibitor of viral replication for HSV1, HSV2, HZV, 
EBV, CMV, and HHV6 viruses. Ganciclovir has also been 
demonstrated to have an inhibitory effect on the replication of 
the hepatitis B virus (Locarnini et al 1989) and some adenovirus 
strains (Taylor et al 1988). The mean effective dose of ganci-
clovir in vitro for HSV1 and HSV2 in ocular clinical isolates 
is 0.23 μg/mL (Smee et al 1983; Smee et al 1985; Inoue et al 
1989) and corresponds to a very low concentration of active 
substance illustrating ganciclovir in vitro potency. Based on 
this pharmacodynamic proﬁ  le, topical formulations with low 
ganciclovir concentrations are assumed to be effective in ocular 
herpes. Such low concentrations are compatible with active 
substance solubilization in an aqueous vehicle, which is more 
convenient for patients than a greasy formulation.
Virgan® ophthalmic gel, containing GCV 0.15% as the 
active moiety, was developed to produce an ophthalmic form 
of ganciclovir that would meet all of the following criteria:
• Good  tolerance,
•  Viscous form ensuring a prolonged period of retention,
•  Similar tonicity to tears,
•  pH adjusted to a physiological value,
• Sterilizable  (autoclavable),
•  Long and stable shelf life,
•  Antimicrobial protection in conformity with European 
regulations.
Figure 2 Geographic corneal ulcer caused by herpes simplex virus keratitis.
Figure 3 Stromal damage caused by herpes simplex virus keratitis.Clinical Ophthalmology 2007:1(4) 444
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The aqueous gel formulation of Virgan® allows homoge-
neous distribution of the ganciclovir preparation and clini-
cally has shown better tolerability (eg, visual disturbances 
and stinging or burning sensations were lower than acyclovir) 
when compared to other topical ophthalmic herpetic oint-
ments. The GCV 0.15% strength was adopted on the basis of 
preclinical studies in experimental animal models of herpetic 
keratitis, preclinical and clinical pharmacokinetic distribution 
studies, and controlled clinical trials.
Virgan® is supplied in a polyfoil 5 g tube with a drop-
per ﬁ  tting. The gel formulation allows for more prolonged 
contact time with the eye than an oil-based formulation. 
Because of its solubility, the aqueous gel allows for a GCV 
concentration of 0.15%, which has demonstrated good toler-
ability and efﬁ  cacy in the local treatment of superﬁ  cial acute 
herpetic keratitis. Its pH is 7.45 and its osmolarity is 300 
mOsmol, and both were adjusted to values close to normal 
physiologic values.
Preclinical studies with ganciclovir
Ganciclovir ophthalmic gel, 0.15% (Virgan®; Laboratoires 
Théa) is a potent drug and has been found to be effective in 
animal herpetic keratitis models at much lower concentra-
tions (0.15%) than effective doses achieved with acyclovir 
ointment (3%). When administered topically 5 times per day 
for 6 weeks, it is well tolerated in animals, and was found to 
penetrate rapidly and maintain effective antiviral concentra-
tions in the anterior segment of the eye.
Preclinical efﬁ  cacy studies
In an experimental model of herpetic keratitis in rabbits 
(Trousdale et al 1984), ganciclovir ointment demonstrated 
antiviral activity at a concentration of 0.1% with no positive 
ocular viral samples after 5 times a day treatment at 12 days 
and at 14 days when applied 3 times a day. Using this same 
model, Castela et al (1994) showed that ganciclovir gel at 
concentrations of 0.2%, 0.05%, and 0.0125% applied 4 times 
a day for 12 days, starting on day 3 after infection, effectively 
treated herpetic keratitis. Ocular isolates showed no positive 
viral samples on day 12 with GCV 0.2% and 0.05%, and on 
day 14 with GCV 0.0125%.
Additionally, Shiota and colleagues (1987) found that, 
after topical application in rabbits, ganciclovir ointment at 
concentrations ranging from 0.03% to 1% was capable of 
preventing herpetic keratitis. Treatment began 1 hour after 
bilateral inoculation of the HSV1 virus and continued 5 times 
a day for 2 days.
When ganciclovir solution and ointment were compared 
in mice infected with ocular HSV (Inoue et al 1989), solu-
tions of 0.3% and 0.03% were shown to be as effective as 
the ointments with the same concentrations.
Preclinical tolerance studies
The tolerance of GCV gel when applied topically to the 
eye has also been evaluated in animals. In the rabbit, GCV 
gel 0.15% preserved with either benzalkonium chloride 
0.0075% or sodium mercurothiolate 0.006% did not cause 
ocular irritation (Iris-Pharma 1992a) or any local anesthetic 
effects (Iris-Pharma 1992b). After 5 daily applications for 
8–10 days in rabbits, GCV gel did not alter the rate of cor-
neal re-epithelialization. Additionally, a 6-week tolerance 
study (Bio-Tox 1990) in rabbits also established the ocular 
tolerance of GCV gel.
Preclinical distribution studies
After topical application of GCV 0.15%  ganciclovir was 
found to be rapidly distributed through the anterior segment 
disease-targeted ocular tissues in male rabbits at concen-
trations higher than the ED50 concentrations measured in 
vitro in HSV1 and HSV2 (Iris-Pharma 1990; Iris-Pharma 
1991).
Clinical studies with ganciclovir
Pharmacokinetic studies in healthy 
volunteers
GCV ophthalmic gel was well tolerated by healthy volunteers 
(Clirophta 1994a). In a randomized, double-masked study 
of 10 subjects, the local tolerance of GCV 0.15% (preserved 
with benzalkonium chloride) was compared with its vehicle 
after repeated administrations. GCV 0.15% was administered 
to one eye and the vehicle gel was administered to the other. 
Both were applied 5 times daily for 7 days.
Figure 4 Structure of ganciclovir.
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Assessment criteria included both subjective measures 
and ophthalmologic examination at the preinclusion visit, 
on the day of inclusion (before the ﬁ  rst administration and 
30 minutes after the ﬁ  rst administration), and on the second 
and seventh day of treatment. Additionally, a standard general 
purpose examination was conducted at the preinclusion visit 
and after 7 days of treatment.
All 10 enrolled volunteers completed the trial. Overall, 
tolerance was good, with only mild anomalies (no clinical con-
sequences) reported. No changes were observed in the physical 
examination between the preinclusion visit and the ﬁ  nal study 
visit, and systemic absorption of GCV was minimal.
A separate study conducted on healthy volunteers evalu-
ated the kinetics of ganciclovir in tears after repeated instilla-
tions of GCV 0.15% (Clirophta 1994b). In this phase I study, 
6 healthy male volunteers instilled one dose of GCV 0.15% 
ophthalmic gel into each eye at 3-hour intervals for 12 hours 
(total of 4 instillations). This dosing frequency was chosen 
based on the usual dosing frequency for the initial treatment 
of superﬁ  cial herpetic keratitis.
Before the ﬁ  rst instillation, and 2 hours and 45 minutes after 
the four instillations, the tears of each eye were collected using 
a technique similar to Schirmer’s test. Paper strips were used 
to collect approximately 10 mm of tears. High-performance 
liquid chromatography was used to measure the concentration of 
ganciclovir in the tears. The detection limit was 4 ng/strip, with 
a maximum limit of 200 ng/strip. All analyses were masked. 
Additionally, ophthalmic examinations were performed at the 
preinclusion visit and before and after each tear sampling. None 
of the study participants experienced signiﬁ  cant discomfort. The 
mean application time of the paper strips was 72 seconds, with 
a minimum of 8 seconds and a maximum of 376 seconds.
In this study, there was a wide range of inter-individual 
and intra-individual variations in the ganciclovir concentra-
tion in the tears. This is most likely due in part to the difﬁ  culty 
of collecting tears with the strips, which may have induced 
reﬂ  ex tearing. The mean concentration of ganciclovir ranged 
from 0.92 to 6.86 μg/mL. These concentrations are greater 
than the inhibitory concentrations for the HSV1.
Overall tolerance to ganciclovir was good. The inherent 
irritation of obtaining samples with Schirmer’s strips led to 
mild conjunctival hyperemia in 5 study participants.
Safety and efﬁ  cacy trials in patients with 
herpetic keratitis – the results of four 
clinical trials
Virgan® was developed for the treatment of acute superﬁ  -
cial herpetic keratitis as a replacement for earlier and less 
effective or less well tolerated antivirals, such as idoxuridine, 
vidarabine, and triﬂ  uridine. Virgan® was ﬁ  rst approved in 
France in 1995, and in clinical trials, it was compared to 
ACV 3%, which was the standard of care at that time in 
Europe. However, Virgan® is available as a gel and ACV 
is available as an ointment, so it is impossible to conduct 
a double-masked study with these two formulations. No 
clinical trials have been conducted that compare Virgan® 
to TFT, which is the current standard of care for herpetic 
keratitis in the US.
Four clinical trials have been conducted to assess the 
efﬁ  cacy and safety of ganciclovir ophthalmic gel (listed as 
Studies A, B, C, and D below). Inclusion criteria were the 
same for all four studies. Patients had to have a dendritic 
or geographic ulcer, but no virologic conﬁ  rmation was 
necessary for inclusion. Dendritic ulcers are pathognomonic 
of a corneal HSV infection and can be distinguished from 
dendrites occurring with herpes zoster or pseudodendrites 
observed with amebic keratitis. Geographic ulcers are gen-
erally not difﬁ  cult to diagnose because of their distinctive 
form. Additionally, most virologic techniques for detecting 
HSV are relatively insensitive and are often a source of 
false-negative results.
Patients were excluded if they had used an antiviral 
treatment in the previous 14 days, if they had severe stro-
mal disease, if they had keratouveitis, if they had previous 
keratoplasties of the affected eye, if they had corneal or 
conjunctival bacterial secondary infection, if they had recent 
ocular trauma (except phototrauma), or if the visual acuity 
of the contralateral eye was less than 2/10.
Other general exclusion criteria included a known hyper-
sensitivity to ganciclovir or acyclovir, leukopenia, known 
anemia or thrombocytopenia, pregnancy or breast feeding, 
known HIV infection, known immune deﬁ  ciency, or previous 
tissue transplantation.
Study A
The ﬁ  rst study included 67 eyes in 66 patients who were treated 
in four centers (Tunis, Dakar, Sousse, and Bamako) in Africa 
from April 1990 through May 1992 (Transphyto 1993a; Colin 
et al 1997). Patients were treated with GCV 0.15%, GCV 
0.05%, or ACV 3% 5 times daily until healing of the ulcer and 
then 3 times daily for 1 week. Patients were excluded from the 
study if their ulcer had been present for more than 14 days or 
if they were younger than 12 years of age. The 67 eyes were 
divided into three groups. Twenty-three eyes received GCV 
0.15%, 22 eyes received ACV 3% ointment, and 22 eyes 
received GCV 0.05%.Clinical Ophthalmology 2007:1(4) 446
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All eyes were included in the intention-to-treat (ITT) 
analysis. Eight eyes were excluded from the per protocol (PP) 
analysis because the observations violated the study protocol 
(typically missed treatments). The PP analysis included 59 
eyes (20 in the GCV 0.15% group, 18 in the ACV group, 
and 21 in the GCV 0.05% group).
The results of the ITT and PP analyses were similar. 
The patient groups were comparable demographically and 
ophthalmologically at the time of inclusion in the study.
In the ITT analysis, the rate of healing was 82.6% for the 
GCV 0.15% group, 77.3% for the GCV 0.05% group, and 
72.7% for the ACV group. Additionally, the median healing 
time was 7 days in the GCV 0.15% and GCV 0.05% groups 
and 8 days in the ACV group, and the number of relapses 
was 1 in the GCV 0.15% and GCV 0.05% groups and 3 in 
the ACV group (Table 2).
The rate of study withdrawals was 13% in the GCV 
0.15% group, 27.3% in the GCV 0.05% group, and 31.8% 
in the ACV 3% group, most likely due to tolerance issues. 
Investigators were asked to assess the efﬁ  cacy of the 3 
treatments on Day 14: 71.43% assessed the efﬁ  cacy of 
GCV 0.15% as very satisfactory, compared to 66.67% for 
GCV 0.05% and 52.63% for ACV 3%. In the ITT analyses, 
a tendency emerges in favor of GCV 0.15% in comparison 
with GCV 0.05% and a slightly superior efﬁ  cacy of GCV 
0.05% compared with ACV 3%. During this clinical trial, a 
viral kinetic study of repeated conjunctival samples seemed 
to indicate an identical rate of disappearance of the virus in 
GCV 0.15% and ACV 3%, while that of GCV 0.05% appears 
less efﬁ  cacious.
GCV 0.15% and 0.05% were well tolerated, and 
stinging and burning sensations appeared to be less com-
mon compared with ACV 3%. Additionally, the rates 
of toxic superficial punctate keratitis were comparable 
(Table 3).
Systemically, no hematologic effects were observed. A 
plasma sample was evaluated on day 14 in 11 patients in 
the GCV 0.15% group and in 13 patients in the GCV 0.05% 
group both 30 minutes and 1 hour after the last instillation. 
The mean cumulative level of exposure to treatment was 
2968.6 μg in the GCV 0.15% group and 1015 μg in the GCV 
0.05% group. The sensitivity threshold of the method was 
5 ng/mL. The mean plasma ganciclovir level values were 
12.7 ± 3.7 ng/mL in the GCV 0.15% group and 22.6 ± 10.4 
ng/ml in the GCV 0.05% group. For both of these groups, 
the plasma ganciclovir concentrations found after 2 weeks of 
treatment were approximately 100-fold less than the typical 
residual plasma concentrations observed in patients treated 
with intravenous ganciclovir (Cytovene®-IV; Vidal 2000), 
which corresponds to concentrations 600-fold lower than the 
maximum concentration.
Study B
A second clinical trial was conducted at 4 study centers 
located in France (Brest, Clermont-Ferrand), Switzerland 
(Lausanne), and the United Kingdom (Bristol) from Decem-
ber 1990 through May 1992 (Transphyto 1993b; Colin et al 
1997). The study included 37 patients: 19 patients were 
treated with GCV 0.15% gel and 18 patients were treated 
with ACV 3% ointment. Patients were given either GCV or 
ACV 5 times daily until healing of the ulcer and then 3 times 
daily for 1 week. Patients were excluded from the study if 
their ulcer had been present for more than 14 days or if they 
were younger than 18 years of age.
The GCV 0.15% and ACV 3% groups were comparable 
at the time of inclusion in the study. A total of 37 subjects 
were enrolled in Study B; 19 subjects receiving GCV 0.15% 
and 18 subjects receiving ACV 3%. Out of these subjects, 
there was 1 subject in each group who was treated but found 
to be misdiagnosed as having a herpetic ulcer. Therefore, 
the efﬁ  cacy analysis included all patients except for the 2 
included in error (n = 18 and n = 17, respectively). However, 
the investigators considered all of the enrolled subjects (n = 19 
and n = 18, respectively) in the tolerance analysis.
Table 2 Summary of efﬁ  cacy results (Study A)
Efﬁ  cacy measure  GCV 0.15%    GCV 0.05%    ACV 3%     p value *
No. of subjects  ITT  PP  ITT  PP  ITT  PP
 N  = 23  N = 20  N = 22  N = 21  N = 22  N = 18
Recovery at Day 14 (%)  19 (82.6)  17 (85)  17 (77.3)  17 (81)  16 (72.7)  13 (72.2)  ns
Relapses by Day 14 (%)  1 (4.3)  1 (5.0)  1 (1.45)  1 (4.76)  3 (13.6)  2 (11.1)  ns
Withdrawals due to worsening   3 (13)  3 (15)  6 (27.3)  5 (23.8)  7 (31.8)  6 (33.3)  ns
condition or complications (%)
Time to healing (median days)  7  7  7  7  8  10  ns
*Statistical signiﬁ  cance was evaluated for between-group differences.
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ITT, intention to treat; ns, not signiﬁ  cant; PP, per protocol.Clinical Ophthalmology 2007:1(4) 447
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This study found that GCV 0.15% was at least as 
effective as ACV 3% in healing the ulcers (Table 4). The 
rate of healing in the GCV 0.15% group was 83.3%, and 
the rate of healing in the ACV 3% group was 70.6%. The 
median time of healing was 6 days for GCV 0.15% and 
7 days for ACV 3%. There were no recurrences for GCV 
0.15% and 1 for ACV 3%. Additionally, 11.1% of GCV 
0.15% patients and 41.2% of ACV patients withdrew from 
the study due to worsening of the ulcer or complications. 
While only 35 patients were included in the efﬁ  cacy 
analysis, all 37 patients receiving the test agents were 
included in the tolerance analysis. Local tolerance was 
signiﬁ  cantly better in the GCV 0.15% group. In the GCV 
0.15% group, 38.5% of patients experienced blurred vision 
lasting longer than 5 minutes after instillation compared 
with 76.9% of patients in the ACV group. Additionally, 
16.7% of GCV 0.15% patients and 50% of ACV patients 
experienced burning or stinging sensations. According 
to the investigators’ observations, there were no cases of 
superﬁ  cial punctate keratitis that were found to be toxic. 
Investigators and study subjects were asked to assess the 
tolerance of the study drug during the trial. In the GCV 
0.15% group, 100% of investigators and 100% of patients 
rated the general tolerance of GCV 0.15% to be “excel-
lent”. In the ACV 3% group, these percentages were 75 
and 67, respectively.
Study C
In the third study, which included 109 patients and was 
conducted from May 1991 to October 1992 at one study 
center in Karachi, Pakistan, GCV 0.15% was found to be at 
least as effective as ACV 3% (Transphyto 1993c). Patients 
were divided into 3 groups: 36 patients were treated with 
GCV 0.15%, 38 patients were treated with ACV 3%, and 
35 patients were treated with GCV 0.05%. Patients were 
treated 5 times daily for 10 days. Patients were excluded 
if their ulcer had been present for more than 7 days or if 
they were younger than 5 years of age.
In the ITT population, the healing rate was 86.1% with 
GCV 0.15%, 80.0% with GCV 0.05%, and 71.05% with 
ACV. The median time to healing was 7 days with ACV, 6 
days with GCV 0.15%, and 4 days with GCV 0.05%. There 
were 3 relapses with ACV, compared to 0 with GCV 0.15% 
and 2 with GCV 0.05%. Additionally, 21.05% of ACV 
patients, 11.4% of GCV 0.05% patients, and 5.6% of GCV 
0.15% patients withdrew from the study due to complica-
tions (Table 5). The withdrawals were all treatment failure-
related, primarily due to worsening condition (eg, stromal 
damage, hypopyon) or to problems of therapeutic efﬁ  cacy 
(ie, increase in ulcer size, lack of healing, relapse). Stromal 
damage was found in 62.5% of the acyclovir withdrawals, 
compared to only 50% in both the GCV 0.15% and GCV 
0.05% withdrawals.
The tolerability was acceptable for all 3 treatment groups. 
Mild stinging or burning were reported from 1 subject in the 
GCV 0.15% group, 5 subjects in the GCV 0.05% group, and 
3 subjects in the ACV 3% group. The number of superﬁ  cial 
punctate keratitis cases that appeared or were exacerbated 
while receiving treatment was similar across the treatment 
groups. Finally, no hematological effects were observed.
Study D
The fourth clinical study took place in Europe from September 
1992 through September 1994 and included 164 patients at 28 
Table 3 Summary of tolerance results, ITT population (Study A)
Tolerance measure  GCV 0.15%  GCV 0.05%  ACV 3%  p value
no. of subjects  N = 23  N = 22  N = 23
Blurred vision  3  3  3  ns
Blurred vision 5 min.  0  0  0  ns
Stinging and burning  4  5  10  p = 0.10*
Toxic superﬁ  cial punctate keratitis   3  0  2  ns
related to treatment at Day 14
*Chi squared test.
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ITT, intention to treat; ns, not signiﬁ  cant.
Table 4 Summary of efﬁ  cacy results, PP population (Study B)
Efﬁ  cacy measure  GCV 0.15%  ACV 3%  p value
no. of subjects  N = 18  N = 17 
Recovery at Day 14 (%)  15 (83.3)  12 (70.6)  ns
Relapses by Day 14 (%)  0  1 (5.9)  ns
Withdrawals due to worsening   2 (11.1)  7 (41.2)  0.06†
condition or complications (%)
Time to healing (median days)  6  7  0.056*
†Fisher’s exact test; *Logrank test; ns = not signiﬁ  cant.
Abbreviations: ACV, acyclovir GCV, ganciclovir; ns, not signiﬁ  cant; PP, per protocol.Clinical Ophthalmology 2007:1(4) 448
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study centers in the following locations: Aulnay-Sous-Bois, 
Bamako, Birmingham, Bobigny, Bordeaux (2 centers), Brest, 
Bristol, Chambery, Chateaulin, Clermont-Ferrand (5 sites), 
Cournon, Dublin, Le Golfe Juan, Lesneven, London, Marseille, 
Palaiseau, Paris (2 sites), Sousse, Tananarivo, Thiers, and 
Toulon (Transphyto 1994; Hoh et al 1996). Patients were 
given either GCV 0.15% or ACV 3% 5 times daily until heal-
ing of the ulcer and then 3 times daily for 1 week. Patients 
were excluded if their ulcer had been present for more than
7 days or if they were younger than 18 years.
The data relating to dendritic and geographic ulcers 
were analyzed separately. A breakdown of study population 
by ulcer type and treatment group is provided in Table 6. 
Overall, 138 patients presented with dendritic ulcers: 67 in 
the ACV 3% group and 71 in the GCV 0.15% group. The 
number of observations was 62 for ACV 3% and 64 for GCV 
0.15%. The treatment groups were homogenous in terms of 
demographic characteristics, prognostic factors, and distribu-
tion of protocol violations.
The clinical study results showed that GCV 0.15% was 
as at least as effective as ACV 3% for the treatment of acute 
herpetic keratitis (Table 7). The efﬁ  cacy results for dendritic 
ulcers of the ITT and PP analyses were similar. Because so 
few patients had geographic ulcers, a statistical comparison 
was not conducted.
In the ITT dendritic ulcer groups, the percent healed on 
Day 14 were 88.7% in the GCV 0.15% group and 91% in 
the ACV 3% group, and in the PP group, the percent healed 
were 92.2% and 93.6%. The median time to healing was 
7 days for the ITT analysis for both treatment groups, and 
6 days and 7 days for the PP analysis for the GCV 0.15% and 
ACV 3% groups, respectively. None of these results were 
statistically signiﬁ  cant.
GCV 0.15% showed similar rates of withdrawals due 
to exacerbation or complications compared to the ACV 
3% group. There were 2 subjects with dendritic ulcers that 
relapsed in each treatment group.
The local tolerance results in this study for subjects in the 
GCV 0.15% group proved to be better than for those in the 
ACV 3% group (Table 8). There were fewer subjects treated 
with GCV 0.15% reporting blurring, which was signiﬁ  cant at 
all time points for the subjects with dendritic ulcers, and the 
average duration of blurring was signiﬁ  cantly shorter at all 
of the evaluation time points except for Day 14 for the GCV 
0.15% group. There were fewer subjects reporting a stinging 
or burning sensation in the GCV 0.15% group (p = 0.03) at 
Day 14. Also, the frequency of toxic superﬁ  cial punctate kera-
titis was reduced by half in the GCV 0.15% group compared 
with the ACV group, and the proportion of cases where the 
investigator judged the tolerance to the product as excellent 
was signiﬁ  cantly higher in the GCV 0.15% group compared 
with the ACV group. Similarly, patients reported that the 
overall tolerance with GCV 0.15% was more frequently 
considered excellent compared with ACV.
Table 5 Summary of efﬁ  cacy results (Study C)
Efﬁ  cacy measure  GCV 0.15%     GCV 0.05%     ACV 3%     p value
No. of subjects  ITT  PP  ITT  PP  ITT  PP
 N  = 36  N = 23  N = 35  N = 21  N = 38  N = 17 
Recovery at Day 14 , n (%)  31 (86.1)  21 (91.3)  28 (80)  19 (90.5)  27 (71.1)  15 (88.2)  ns
Relapses,  %  0  0  5.7  4.8 7.9 11.8  ns
Withdrawals due to worsening   5.56  0  11.4  4.8  21.1  23.5  p = 0.02*
condition or complications, %
Time to healing, median days  6  6  4  4  7  6  ns
*PP group only.
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ITT, intention to treat; ns, not signiﬁ  cant; PP, per protocol.
Table 6 Subject population by ulcer type and treatment (Study D)
Treatment groups  Dendritic ulcers – number of subjects  Geographic ulcers –
 ITT  PP  number of subjects
GCV 0.15% (N = 84)  71  64  13
ACV 3% (N = 80)  67  62  13
Total 138  126  26
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ITT, intention to treat; PP, per protocol.Clinical Ophthalmology 2007:1(4) 449
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The original statistical analysis conducted for Study 
D was based on a superiority hypothesis with a 20% 
improvement in recovery rate expected for GCV 0.15% 
compared to ACV 3%. At the time the study was con-
ducted, methodology for non-inferiority analyses was not 
understood as well as it is today. The sample size for the 
study was based upon a superiority analysis. Since the 
results showed comparable efficacy between GCV 0.15% 
and ACV 3%, the study failed to meet the superiority 
margin required.
Table 7 Summary of efﬁ  cacy results by ulcer type (Study D)
Efﬁ  cacy measure  Dendritic ulcers    Geographic ulcers  p value
No. of subjects  ITT   PP   
Recovery at Day 14- (%)
GCV 0.15%  63 (88.7)  59 (92.2)  11 (84.6)  ns
ACV 3%  61 (91)  58 (93.6)  12 (92.3)
Withdrawals due to exacerbation
or complication (%)
GCV 0.15%  9 (12.37)  6 (9.37)  2 (15.38)  ns
ACV 3%  7 (10.45)  6 (9.67)  2 (15.38)
Time to healing (median days)
GCV 0.15%  7  6  9  ns
ACV 3%  7  7  7
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ITT, intention to treat; ns, not signiﬁ  cant; PP, per protocol.
Table 8 Summary of local tolerance results by ulcer type (Study D)
GCV 0.15%
(N = 70)*
ACV 3%
(N = 66)*
p Value†
Blurring: % subjects; range across visits through Day 14
Dendritic ulcers
Geographic ulcers
28.1– 45.7
0–30
50.9–63.6
14.3–53.9
p  0.02 at all time points, except 
Day 10 where p = 0.056
Stinging/burning: % subjects; range across visits 
through Day 14
Dendritic ulcers
Geographic ulcers
9.3–21.43
20–25
14.3–26.42
38.5–50
p = 0.03 at Day 14 
Duration of blurring (sec): range across visits 
through Day 14
Dendritic ulcers
Geographic ulcers
164–301
20–120
474–972
120–644.28
p  0.04 at all time points, except 
Day 14 where p = 0.056
Duration of stinging/burning (sec): range across visits 
through Day 14
Dendritic ulcers
Geographic ulcers
100–223
10–260
148–745
55–150
ns
Toxic SPK: % subjects; range across visits through D14
Dendritic ulcers
Geographic ulcers
3.7–7.9
0
6.1–16.98
15–43
p = 0.03 at Day 10
Investigator assessment of tolerance, excellent, at 
Day 14 (%):
Dendritic ulcers
Geographic ulcers
56 (78.87)
12 (92.31)
29/66 = 43.94
6 (46.15)
p = 0.00006 at all time points
Subject assessment of tolerance, excellent, at Day 14 (%)
Dendritic ulcers
Geographic ulcers
52/69 = (75.36)
10 (90.91)
28/66 = (42.42)
4 (30.77)
p = 0.0002 at all time points
*Number of patients included for assessment of tolerance (investigatory and subject) and for adverse events.
Abbreviations: ACV, acyclovir; GCV, ganciclovir; ns, not signiﬁ  cant; SPK, superﬁ  cial punctate keratitis.Clinical Ophthalmology 2007:1(4) 450
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Recently, a non-inferiority analysis was conducted using 
the original data obtained (data on ﬁ  le). A non-inferiority mar-
gin of 18.5% was selected based upon an analysis of published 
studies. The non-inferiority analysis conducted on Study D 
showed that the lower 95% conﬁ  dence interval around the 
difference in proportions between GCV 0.15% and ACV 3% 
was no greater than the non-inferiority margin, and hence the 
non-inferiority of ganciclovir to acyclovir in Study D, across 
ulcer types and time points, was established.
Antiviral resistance
The risk of emergence of viral strains resistant to ganci-
clovir is low and has been found to be similar to acyclovir 
(Goldschmidt et al 1994). These antiviral drugs are structur-
ally closely related and have similar mechanisms of action, 
so there is cross-resistance to these two drugs. Both in vitro 
and in vivo, and under selective pressure with idoxuridine, 
it is possible to obtain strains of HSV1 and HSV2 that are 
resistant to acyclovir, and in most cases, these strains show 
cross-resistance to ganciclovir. Viral strains can eliminate or 
alter the kinase so that the drug is not phosphorylated, but most 
of these mutant strains are relatively avirulent. They can also 
alter the DNA polymerase so the drug does not bind, but these 
mutants are very rare. There are no data in the literature that 
suggests an inherent risk of the emergence of new strains of 
HSV resistant to ganciclovir and not resistant to acyclovir.
Acyclovir and ganciclovir have been widely used for 
more than 25 years, and HSV resistance to these antivirals 
is sporadic and is generally isolated to immunocompro-
mised populations in the US (Levin et al 2004) and in other 
countries (Greco et al 2007; Morﬁ  n and Thouvenot 2003). 
In fact, in immunocompetent patients in the US, only 0.1% 
to 0.7% of clinical ocular isolates show resistance in vitro 
(Levin et al 2004).
Prophylatic treatment of recurrent 
ocular herpes
Oral acyclovir
The Herpetic Eye Disease Study (HEDS), a large clinical 
study funded by the US National Eye Institute, changed and 
reﬁ  ned treatment and management protocols for herpetic eye 
disease (HEDS 2000). HEDS was undertaken to discover 
several things, including the assessment of low-dose oral 
acyclovir for prevention of recurrent HSV ocular infections 
in patients with previous episodes of herpetic eye disease.
HEDS results showed that long-term suppressive therapy 
with an oral antiviral agent (acyclovir 400 mg bid) reduced 
the recurrence of HSV epithelial keratitis and stromal 
keratitis, produced a 45% decrease in the rate of recurrence 
of all forms of ocular complications, produced a 50% reduc-
tion in the rate of recurrence of HSV stromal keratitis, and 
demonstrated that the beneﬁ  t was greatest among patients 
with prior HSV stromal keratitis.
HEDS also showed that long-term acyclovir therapy was 
not effective in preventing HSV stromal keratitis or iritis in 
patients with HSV epithelial keratitis.
While these results offered advances to ophthalmologists 
treating herpetic eye disease, oral acyclovir still continues 
to be used more as an adjunct to therapy, rather than a stand 
alone treatment.
Ganciclovir ophthalmic gel, 0.15%
A recent prospective interventional case series studied the 
use of topical ganciclovir gel 0.15% for both the treatment 
and prophylaxis of herpetic epithelial keratitis (Tabbara 
2005). The study evaluated the effects of GCV 0.15% for 
the treatment of herpetic keratitis among 16 consecutive 
cases and for the prophylaxis of herpetic keratitis among 6 
of these patients, 3 of whom had a corneal graft. Ten cases 
had epithelial dendritic ulcers and 6 cases had recurrent 
geographic epithelial herpetic corneal ulcers. Topical GCV 
0.15% gel was given to all patients once every 6 hours for 
2 weeks. Complete resolution of herpetic keratitis was noted 
in all patients. During the follow-up observation period, 
none of the 6 patients on prophylactic ganciclovir developed 
a recurrence of herpetic keratitis. Three (30%) of the 10 
patients without prophylaxis developed recurrences of their 
herpetic infection. No ocular side effects from topical use 
of ganciclovir gel were noted. Topical ganciclovir may be 
helpful in the treatment of herpetic epithelial keratitis and in 
the prophylaxis of patients with herpetic keratitis, but larger 
well-controlled trials are needed to validate this ﬁ  nding.
The treatment and prevention of herpetic eye disease 
is expensive (Lairson et al 2003). In fact, approximately 
US$17.7 million is spent annually to treat new and recurrent 
cases in the US. Chronic suppressive oral acyclovir costs 
US$8,532 per ocular HSV episode avoided. This study also 
found that if a more effective antiviral prophylaxis was 
available, the incremental cost per infection avoided would 
decrease by up to 51%.
Antiviral treatment 
of keratoconjunctivitis caused 
by adenovirus
Conjunctivitis and keratoconjunctivitis caused by adeno-
viruses are common and highly contagious. There are Clinical Ophthalmology 2007:1(4) 451
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more than 50 different serotypes of adenoviruses and 
they are considered a major public health risk because 
of their ability to generate epidemics. In both the United 
States and Europe, they are considered the infectious 
agents most commonly involved in external ocular infec-
tions. Adenoviruses usually affect both eyes and patients 
with adenoviruses usually report a clear discharge. These 
patients may also have palpable and painful preauricular 
adenopathy. In children, adenoviral conjunctivitis is often 
accompanied by a fever and sore throat. Adults typically 
experience acute follicular inﬂ  ammatory conjunctivitis 
with occasional hemorrhage. They usually have a red 
painful tearful eye with palpebral edema and foreign body 
sensation. While there is no licensed antiviral product 
available to treat this condition, antiviral agents such as 
ganciclovir may be possible treatments (Duggan et al 1997; 
Tabbara et al 2001; Bruno et al 2003; Naesens et al 2005; 
Kinchington et al 2005).
To limit contamination of the environment, meticulous hand 
hygiene as well as time off from work or school are required. 
These viruses are highly contagious due to the non-enveloped 
structure of the virion. They are resistant to body temperatures 
higher and lower than normal, as well as to changes in osmolar-
ity, pH, and dehydration. Infections are transmitted directly by 
direct contact, in swimming pools, and by exposure to droplet 
nuclei. They are also transmitted indirectly through contact 
with handkerchiefs, utensils, and other objects contaminated 
with body secretions from the infected person.
Drugs active against adenoviral infections include the 
nucleoside analogues, which are prodrugs that required 
activation by a viral or cell enzyme to exercise the antiviral 
effect. Examples include 5-iodo-2′-desoxyuridine, triﬂ  uri-
dine, zalcitabin, stampidine, cidofovir, and ganciclovir.
Acyclovir is inactive against adenoviruses, while gan-
ciclovir is active, but at concentrations higher than those 
usually used for herpes virus inhibition (Table 9).
Tabbara and colleagues (2001) conducted a study that 
examined the comparative effects of ganciclovir ophthalmic 
gel, 0.15%, with the instillation of preservative-free artiﬁ  -
cial tears in 18 patients with adenoviral keratoconjuncti-
vitis. Nine patients received ganciclovir and nine patients 
received artiﬁ  cial tears. In this study, the group treated with 
ganciclovir had a mean recovery time of 7.7 days (range: 
7–12 days) compared with 18.5 days for the patients treated 
with artiﬁ  cial tears (range: 7–30 days). Two patients treated 
with ganciclovir and 7 patients treated with artiﬁ  cial tears 
developed subepithelial opacities. The authors of this study 
concluded that GCV 0.15% topical gel is safe and effective 
for the treatment of adenoviral keratoconjunctivitis. Early 
treatment with ganciclovir would reduce ocular morbidity 
and prevent or modify the severity of subepithelial corneal 
opacities.
Conclusions
Ocular HSV infections are a major cause of corneal 
blindness in the developed world. Ganciclovir ophthal-
mic gel, 0.15% is an effective and well tolerated antiviral 
treatment for superficial acute herpetic keratitis and it 
represents an advance in the treatment of this condition. 
Randomized, multicenter, comparative clinical trials that 
compared GCV 0.15% with ACV 3% ointment found 
that ganciclovir is as effective as acyclovir. Addition-
ally, these clinical trials showed that the local tolerance 
of ganciclovir was better than that with acyclovir, par-
ticularly with regard to blurring and stinging or burning 
sensations assessed after instillation. Since ganciclovir 
is delivered in the form of an aqueous gel, it allows for 
prolonged contact time with the corneal surface. This 
may explain its ability to maintain comparable efficacy 
and better tolerance when compared with oil-based 
ointments.
Commercially available since 1996, GCV 0.15% oph-
thalmic gel is currently marketed as Virgan® by Laboratoires 
Théa in over 30 countries within Europe, Asia, Africa, and 
South America. In January 2007, Sirion Therapeutics, an 
ophthalmic biopharmaceutical company based in Tampa, 
FL, licensed the US rights to this drug. On April 16, 2007, 
ganciclovir ophthalmic gel, 0.15% received orphan drug 
designation for the treatment of acute herpetic keratitis from 
the US Food and Drug Administration (FDA). Sirion plans 
to submit a New Drug Application to the FDA in 2008. If 
this agent is approved for use in the US, it may provide 
patients with a more tolerable, convenient, and effective 
treatment. Based upon its proven safety and efﬁ  cacy, the 
Table 9 Inhibitory activity of ganciclovir on adenovirus
Adenovirus serotype  ED50
1 19.5  μM
2 5.4  μM
4 8.1  μM
6 9.7  μM
8 15.0  μM
10 11.0  μM
19 7.2  μM
22 5.4  μM
28 13.8  μMClinical Ophthalmology 2007:1(4) 452
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introduction of a topical antiviral agent with less toxicity 
and a more convenient dosage regimen such as ganciclovir 
would clearly be a valuable tool for US clinicians who treat 
herpetic keratitis.
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